AVANÇOS TERAPÊUTICOS DA BETA-TALASSEMIA: UMA REVISÃO INTEGRATIVA

Authors

  • Martha de Araujo Medeiros Pereira Graduada em Medicina pelo Centro de Estudos Superiores de Maceió
  • Rhayran Espindola Rodrigues Graduada em Medicina pela Universidade Federal da Grande Dourados
  • Paulo Sérgio de Souza Larrea Graduado em Medicina pela Universidade Federal da Grande Dourados
  • Julianna Miranda Gomes Graduada em Medicina pelo FAHESP/IESVAP- Instituto de Educação Superior do Vale do Parnaíba
  • Matheus Gabriel Bonfim Telles Graduando em Medicina pela Universidade Federal da Grande Dourados
  • Edney Marcelo de Melo Aragão Júnior Graduando em Medicina pelo Centro de Estudos Superiores de Maceió
  • Leonardo Mota Silva Graduando em Medicina pelo Centro de Estudos Superiores de Maceió
  • Markos Paulo Alves Ferreira Graduando em Medicina pelo Centro de Estudos Superiores de Maceió
  • Lucas Alves de Azevedo Graduando em Medicina pelo Centro Universitário de Maceió
  • Lucas Gabriel Lopes Donato Graduando em Medicina pelo Centro Universitário de Maceió
  • Ernesto Brandão de Albuquerque Maranhão Graduando em Medicina pelo Centro Universitário de Maceió
  • Laura Vilela de Medeiros Graduando em Medicina pelo Centro Universitário de Maceió.

DOI:

https://doi.org/10.36557/pbpc.v3i2.123

Keywords:

beta-thalassemia, management and treatment

Abstract

Introduction: Beta-thalassemia is a group of inherited hemoglobinopathic disorders characterized by reduced or absent synthesis of hemoglobin beta chains, resulting in unbalanced hemoglobin production and anemia of varying severity. Methods: This is an integrative review conducted through the Scopus, PubMed®, and SciELO databases, using the descriptors beta-thalassemia, management, and treatment. Studies published in the last 15 years, in English, Spanish, or Portuguese, that addressed the topic were included. Results and discussions: β-thalassemia has three main types: trait, intermedia, and major. Patients with the trait generally do not require treatment, but should receive genetic counseling. Those with β-thalassemia intermedia can lead a normal life with regular monitoring, but may require some interventions. β-thalassemia major requires intensive care, including frequent transfusions and chelation therapy to prevent iron overload. Bone marrow transplantation is the definitive treatment, while new approaches such as gene therapy are under development. Conclusion: The treatment of β-thalassemia varies according to the severity of the disease. Treatment includes several interventions aimed at improving the quality of life and survival of patients.

References

ADEL, N. et al. Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach. Toxicology and Applied Pharmacology, v. 382, p. 114–148, 2019.

AESSOPOS, A. et al. Heart disease in thalassemia intermedia. Hemoglobin, v. 33, supl. 1, p. S170-S176, 2009.

ASADOV, C. et al. Beta-thalassemia intermedia: a comprehensive overview and novel approaches. International Journal of Hematology, v. 108, p. 5-21, 2018.

BORGNA-PIGNATTI, C. et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, v. 89, n. 10, p. 1187-1193, 2004.

CARIO, H. Hemoglobinopathies: Genetically diverse, clinically complex, and globally relevant. European Medical Oncology, v. 11, n. 3, p. 235–240, 2018.

CIHAN, M. K. et al. The impact of transfusion and chelation on oxidative stress in immigrant Syrian children with β-thalassemia. Indian Journal of Hematology and Blood Transfusion, v. 33, n. 4, p. 552–558, 2017.

CRICHTON, R. R.; WARD, R. J.; HIDER, R. C. The efficacy of iron chelators for removing iron from specific brain regions and the pituitary—ironing out the brain. Pharmaceuticals, v. 12, n. 3, p. 138, 2019.

GALANELLO, R.; ORIGA, R. Beta-thalassemia. Orphanet Journal of Rare Diseases, v. 5, n. 1, p. 11, 2010.

JEENGAR, R. K. et al. Red cell alloimmunization in repeatedly transfused children with beta thalassemia major. International Journal of Contemporary Pediatrics, v. 4, n. 3, p. 775–779, 2017.

KUMAR, R.; SHARMA, D. C.; KISHOR, P. Hb E/β-Thalassemia: The second most common cause of transfusion-dependent thalassemia in the Gwalior-Chambal region of central India. Hemoglobin, v. 36, n. 5, p. 485–490, 2012.

MODELL, Bernadette; DARLISON, Matthew. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization, v. 86, n. 6, p. 480-487, 2008.

MUTAR, M. T. et al. Awareness among parents of beta thalassemia major and intermedia patients in three centers in Baghdad and Al-Nasiriyah, Iraq in 2017. International Journal of Medical Sciences, v. 7, n. 1, p. 6–10, 2019.

ORIGA, R. Combination therapies in iron chelation. Thalassemia Reports, v. 4, n. 3, p. 452, 2014.

PACE, B. S. et al. Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: strategies to treat sickle cell disease. Experimental Biology and Medicine, v. 240, n. 8, p. 1050-1064, 2015.

RUND, Deborah. Thalassemia 2016: Modern medicine battles an ancient disease. American Journal of Hematology, v. 91, n. 1, p. 15-21, 2016.

SABLOFF, M. et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood, v. 117, n. 5, p. 1745–1750, 2011.

SARKER, N. R. et al. Recent advances in the management of Thalassaemia: A Review Update. Journal of ShaheedSuhrawardy Medical College, v. 6, n. 1, p. 31–37, 2014.

TAHER, A. T. et al. Age-related complications in treatment-naïve patients with thalassaemia intermedia. British Journal of Haematology, v. 150, n. 4, p. 486-489, ago. 2010.

TAHER, A. T.; CAPPELLINI, M. D. How I manage medical complications of β-thalassemia in adults. Journal of American Society and Hematology, v. 32, n. 17, p. 1781–1791, 2018.

TAHER, A.; VICHINSKY, E.; MUSALLAM, K.; CAPPELLINI, M. D.; VIPRAKASIT, V. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia: Thalassaemia International Federation, 2013.

TARI, K. et al. Thalassemia an update: Molecular basis, clinical features and treatment. International Journal of Biomedicine and Public Health, v. 1, n. 1, p. 48–58, 2018.

YANG, J. et al. Induced pluripotent stem cells in Alzheimer’s disease: Applications for disease modeling and cell‐replacement therapy. Molecular Neurodegeneration, v. 11, n. 1, p. 39, 2016.

Downloads

Published

2024-08-15

Issue

Vol. 3 No. 2 (2024): PBPC 2024

Section

Ciências da Saúde

License

Copyright (c) 2024 Martha de Araujo Medeiros Pereira , Rhayran Espindola Rodrigues , Paulo Sérgio de Souza Larrea , Julianna Miranda Gomes , Matheus Gabriel Bonfim Telles, Edney Marcelo de Melo Aragão Júnior , Leonardo Mota Silva, Markos Paulo Alves Ferreira, Lucas Alves de Azevedo, Lucas Gabriel Lopes Donato , Ernesto Brandão de Albuquerque Maranhão , Laura Vilela de Medeiros

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Você tem o direito de:

  1. Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
  2. Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
  3. O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.  

 

De acordo com os termos seguintes:

  1. Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
  2. Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.